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ABSTRACT 
Background 
Falls are a major health and injury problem for people with Parkinson’s disease (PD). Despite 
the severe consequences of falls, a major unresolved issue is the identification of factors that 
predict the risk of falls in individual PD patients. The primary aim of this study was to 
prospectively determine an optimal combination of functional and disease-specific tests to 
predict falls in individuals with PD. 
 
Methods 
One-hundred and one people with early stage PD undertook a battery of neurological and 
functional tests in their optimally medicated state. The tests included Tinetti, Berg, Timed Up 
and Go, Functional Reach and the Physiological Profile Assessment of falls risk: the latter 
assessment includes physiological tests of visual function, proprioception, strength, cutaneous 
sensitivity, reaction time and postural sway. Falls were recorded prospectively over six 
months.  
 
Results 
Forty-eight percent of participants reported a fall and 24% more than one fall. In the 
multivariate model, a combination of the UPDRS total score, total freezing of gait score, 
occurrence of symptomatic postural orthostasis, Tinetti total score and extent of postural 
sway in the anterior-posterior direction produced the best sensitivity (78%) and specificity 
(84%) for predicting falls. From the UPDRS items, only the rapid alternating task category 
was an independent predictor of falls. Reduced peripheral sensation and knee extension 
strength in fallers contributed to increased postural instability.  
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Conclusions 
Falls are a significant problem in optimally medicated early stage PD. A combination of both 
disease-specific and balance- and mobility-related measures can accurately predict falls in 
individuals with PD.  
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INTRODUCTION 
There is a high occurrence of falls in PD (40-70%)1 which occur during daily activities and 
when patients are optimally medicated.2  Falls lead to injuries,3 fear of falling,4 reduced 
mobility and a concomitant development of weakness,5, 6 deterioration of fitness, loss of 
independence, increased risk of nursing home admission,7 and reduced survival.8 This 
impacts upon the health care system and the broader community.9, 10  Consequently there is a 
need to identify falls risk predictors relevant to PD as this is critical for prescribing 
appropriate treatments and interventions. 
 
Currently there are limitations in falls risk assessments for people with neurological disease.11  
Although “generic” falls risk tests have been developed for the general elderly population, it 
is uncertain whether these measures are equally sensitive for people with PD, whose hallmark 
characteristic balance and gait deficits are unique.2 
 
Seven prospective studies12-18 have produced inconsistent findings in their search for 
clinically useful falls risk factors.  Possible risk factors included disease duration, dementia, 
symmetrical disease onset, loss of arm swing,18 prior falls and disease severity,12-14 abnormal 
posture, freezing of gait, frontal impairment, poor balance and leg weakness.17  The most 
robust clinical predictor was two or more falls in the previous year1 but this is of limited use 
for treatment planning and ideally intervention should occur before the first fall has occurred. 
 
The aim of this study was to prospectively determine falls risk factors, the effectiveness of 
different functional tests and disease-specific clinical assessments to predict falls, and to 
develop a multivariate predictive model. 
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METHODS 
We used an observational cohort design to assess Parkinson’s disease patients on a series of 
clinical and functional tests at baseline. Participants were then followed up for 6 months 
while they reported their daily incidence of falls using monthly calendars. 
 
Participants 
One-hundred and thirty people with a diagnosis of Parkinson’s disease were recruited from 
community support groups and neurology clinics in South-East Queensland from March 2002 
until December 2006.  Participants were independently living in the community and were 
required to be able to walk without the use of any aids. A cohort size of 100 people was 
determined to provide sufficient sample size based on previous prospective studies of falls in 
PD.14, 18 
 
Standard Protocol Approvals, Registrations, and Patient Consents. 
Ethics approval for this study was received from the Queensland University of Technology 
Human Research Ethics Committee. All participants gave informed consent to participate in 
accordance with Queensland University of Technology ethics guidelines, consistent with the 
Declaration of Helsinki. 
INSERT TABLE 1 ABOUT HERE. 
 
Assessments 
Demographic data including height, weight, body mass index and current medications were 
recorded. Participants were assessed on the Mini Mental State Exam (MMSE),19 the freezing 
of gait (FOG) questionnaire,20 the Schwab and England (S&E) activities of daily living 
scale.21  The UPDRS was assessed for each subscale: I mentation, behaviour, mood, II 
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activities of daily living, III motor function, IV complications of therapy.  A measure of 
postural instability and gait disability (PIGD) was derived from the UPDRS (sum of items 
13-15, 27-30). 
 
Balance, gait and falls risk were assessed using the following widely used functional tests: 
Tinetti,22 Berg,23 Timed Up and Go (TUG),24 Functional Reach25 and the Physiological 
Profile Assessment (PPA).26  The Tinetti is a qualitative test comprised of two sub-scales, 
which relate to clinical balance and gait, which are combined into a total score.  Similarly, the 
Berg Balance Scale assesses balance during common, everyday tasks, such as turning, single 
leg support, reaching and whilst picking up an object from the floor.  For the TUG test, 
participants arose from a chair, walked three metres, turned around, walked back to the chair 
and sat down.  The PPA assessment includes physiological tests of visual function (visual 
acuity and contrast sensitivity), lower-limb proprioception and cutaneous sensitivity, knee 
and ankle strength, hand and foot reaction time, and postural sway while standing on a firm 
and foam surface with eyes open and closed.  All assessments were undertaken when 
participants were in their optimally-medicated state. 
 
Falls Assessment 
A fall was defined as unintentionally coming to the ground or some lower level not as a result 
of a major intrinsic event (e.g. stroke) or overwhelming hazard.27, 28  Retrospective falls were 
obtained from a questionnaire which asked whether participants had experienced a fall in the 
previous 12 months.  Following the initial assessment each participant was given a set of 
monthly falls calendars to complete and return over a six month period using envelopes with 
prepaid postage.  Participants recorded each fall, where it occurred, and whether they had 
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sustained any injuries.  If participants failed to complete their monthly calendars they were 
sent reminders by mail and received follow-up phone calls. 
 
Statistical Analysis 
Independent samples t- tests were used to examine mean differences between fallers and non-
fallers on continuous variables.  The chi-square (χ2) test was used to assess associations 
between categorical variables.  Receiver Operating Characteristic (ROC) analyses were 
performed to determine the sensitivity and specificity of each variable in predicting fallers.  The 
cut-off value of the test which yielded the “best” sensitivity and specificity was selected as the 
point which simultaneously maximised both on the ROC curve.  An accuracy based on the 
proportion of cases correctly classified using this cut-off was calculated. 
 
A restricted set of variables that were different between fallers and non-fallers (p<0.01) was 
entered into a logistic regression model.  Predicted probabilities from the logistic regression 
equation were examined using ROC analyses to investigate the efficacy of the classification 
function.29  A leave-one-out cross-validation was performed to examine the likely efficacy of 
the model if tested on a different sample.30 
 
The relationship between falls and individual items of the UPDRS was examined by averaging 
symptom scores over different body parts1 and including this as a single regressor in a logistic 
regression.1, 12  Odds ratios and 95% confidence intervals were calculated. 
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RESULTS 
From the 130 people with a diagnosis of Parkinson’s disease who volunteered for the project, 
seven withdrew before attending the testing session, eleven were excluded for medical 
reasons (previous surgery 8, diabetes 1, previous diagnosis of dementia 1, uncertain PD 
medication 1), one used a cane for walking, five did not complete the baseline tests and five 
did not complete the six month follow-up falls calendars.  
 
One-hundred and one people (68 males, 33 females, 66.4±8.2 yrs) completed all baseline 
assessments and follow-up falls calendars. These participants were predominantly early stage, 
had average disease duration since diagnosis of 6.1±4.4 yrs, a Unified Parkinson’s Disease 
Rating Score (UPDRS) of 32.8±13.4, and a Hoehn and Yahr score of 2.1±0.8 (Table 1).  
More participants were of the akinetic-rigid subtype (77.1%) than the tremor-dominant 
(19.5%) or mixed subtypes (3.4%) as determined from the UPDRS scores.31 
 
Falls 
In the six-month follow up period, 48% of participants reported a fall and 24% of participants 
were recurrent fallers (> 1 fall).  Forty two percent of participants reported falling in the 
previous year. 
 
Comparison between Non-Fallers and Fallers 
Fallers had longer disease duration and increased disease severity based on the UPDRS (II, 
III, Total) and the derived PIGD score (Table 1).  From the UPDRS IV (complications of 
therapy) dyskinesia was more often present in fallers than non-fallers. Fallers had a greater 
incidence of symptomatic orthostasis and sleep disturbance.  Fallers scored lower on the S&E 
activities of daily living scale and had higher scores on the FOG questionnaire.  
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Fallers performed more poorly than non-fallers for the Tinetti (Balance, Gait, Total), Berg 
Balance, and Timed Up and Go tests (Table 2).  There were no significant differences in falls 
risk as determined by the PPA.  However, the component physiological tests of the PPA 
revealed that fallers had significantly poorer peripheral sensation, knee extension strength and 
had greater anterior-posterior postural sway when standing on a firm surface compared to 
non-fallers.  
 
Increased touch thresholds were correlated with increased postural sway (eyes open r=.277, 
p=.006; eyes closed r=.293, p=.003) when all participants were considered.  Similarly, 
increased L-Dopa medications were correlated with increased postural sway (eyes open 
r=.224, p=.026; eyes closed r=.239, p=.018).  However, these correlations were not evident 
for the separate faller or non-faller groups. 
 
INSERT TABLE 2 ABOUT HERE. 
 
Sensitivity and Specificity of Clinical Tests 
Despite the significant difference between fallers and non-fallers in many of the measures 
and the significant relationship with falls, there were large variations in the precision 
(sensitivity and specificity) with which each measure was able to predict falls.  Table 3 shows 
the outcomes of the ROC analysis for the disease-specific and functional test measures in 
predicting falls. 
 
INSERT TABLE 3 ABOUT HERE. 
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Of the disease specific measures, the UPDRS total score provided the best measure of 
sensitivity (74%) and specificity (63%) followed by the FOG questionnaire (Sensitivity 75%, 
Specificity 59%).  Both of these measures had a similar accuracy (66-67%). Moderate 
precision was achieved by the UPDRS subscales (UPDRS II, III, PIGD) and disease duration.  
The individual UPDRS items that were significantly associated with falls were hand 
movements, rapid alternating tasks, leg agility and rising from a chair (Figure 1).  When all 
UPDRS items were simultaneously included as a multivariate model in the logistic 
regression, only the rapid alternating tasks were associated with falls (Exp(B)=2.244, 
p=0.031, 95%CI=1.076-4.680). 
 
INSERT FIGURE 1 ABOUT HERE. 
 
For the functional tests of balance, mobility and falls risk, similar precision of falls prediction 
was achieved by the Tinetti gait, TUG and PPA tests with sensitivities of 65-69%, 
specificities of 62-69% and accuracies of 63-68%.  Of the significant component tests of the 
PPA, the postural sway on a firm surface provided the best precision with a sensitivity of 
66%, specificity of 68% and accuracy of 67%. 
 
Logistic Regression Model 
To ensure that there was no redundancy in the variables used the UPDRS total and Tinetti 
total scores were used rather than their component scores.  The more objective UPDRS total 
score was used as a measure of disease severity in preference to disease duration.  Other 
variables included were the FOG total score, symptomatic postural orthostasis, and postural 
sway with eyes open on a firm surface.  This multivariate model produced a sensitivity of 
78% and specificity of 84% (Figure 2a).  The leave-one-out validation resulted in a 
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sensitivity of 72% and specificity of 76% (Figure 2c).  The addition of previous falls as a 
variable in this model made only slight changes to the sensitivity (77%) and specificity (82%) 
in the negative direction.  Similar sensitivities (78%) and specificities (84%) were obtained if 
either the UPDRS II or III scores were substituted for the UPDRS total score. 
 
INSERT FIGURE 2 ABOUT HERE. 
 
Prediction of Falls in Previous Non-Fallers 
Of the 59 participants who had not previously fallen, 17 (29%) went on to fall in the 
following six months. For this group there were no significant differences between fallers and 
non-fallers for any of the demographic or disease specific measures. There were also no 
differences on performance of any of the clinical tests. Only the PPA component measures of 
anterior-posterior postural sway when standing on a firm and foam surface with eyes open 
showed a significant increase for the fallers.  These measures had an average sensitivity of 
66% and specificity of 68%. 
 
The application of the multivariate model to these data resulted in a sensitivity of 77% and 
specificity of 76% (Figure 2b).  The leave-one-out validation resulted in a sensitivity of 69% 
and specificity of 72% (Figure 2d). 
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DISCUSSION 
This prospective study of falls in people with PD demonstrated that both disease-specific and 
balance- and mobility-related measures are important for predicting falls.  The multivariate 
model that produced the best sensitivity (78%) and specificity (84%) included UPDRS total 
score, total FOG score, occurrence of symptomatic postural orthostasis, Tinetti total score 
and extent of postural sway in the anterior-posterior direction while standing on a firm 
surface with eyes open.  
 
The incidence of falls was 48% which is comparable to two previous prospective studies14, 
17but lower than that reported by two others.15, 18 The incidence was lower (29%) in those 
patients who had not previously fallen and confirms the findings of a recent meta-analysis.1  
Recurrent falls occurred in 50% of the fallers (24% of all participants).  Fallers were 
predominantly of the akinetic-rigid subtype rather than the tremor dominant subtype which is 
in agreement with previously reported trends.1 
 
The high incidence of falls is particularly notable given that participants were predominantly 
early stage PD, independently living in the community, did not use walking aids and had 
good functional mobility.  Although there were no differences between fallers and non-fallers 
in measures of cognitive impairment as determined by the MMSE and UPDRS I scores, two 
fallers has MMSE scores less than 24, which is regarded as a cut-off for dementia.  Cognitive 
impairment has previously been identified as an independent predictor of falls in PD.17, 18 
 
Both faller and non-faller groups had a wide range of L-Dopa intake, which was also evident 
in an earlier study.18  Increased L-Dopa medications were also slightly but significantly 
correlated with increased postural sway on the firm surface when all subjects were 
considered. Importantly, however, there were differences in symptomatic postural 
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hypotension which can be expected if L-Dopa medications were strongly linked to falls.  
Postural hypotension has also been associated with falls risk in PD.14, 17 
 
The individual UPDRS items that were significantly related to falls included rapid movement 
sequencing tasks of upper (hand movements) and lower limbs (leg agility) as well as rising 
from a chair.  The strongest independent predictor arising from the multivariate UPDRS 
model, however, was that of rapid alternating tasks of the upper limbs. This suggests that 
impairments in sequencing and coordination of multi-joint movements may represent a 
specific falls risk factor that has not been recognized previously. Importantly, the difficulty in 
performing these sequencing tasks occurs in the arms rather than the legs. The upper 
extremities normally play a minimal role in the maintenance of postural stability and this 
factor may therefore indicate a higher-level cognitive deficit. People with PD have 
difficulties in movement sequencing tasks.32  Changes in the pre-supplementary and 
supplementary motor area, regions implicated in the control of movement sequences, have 
also been reported for PD.33, 34  Deficits in the initiation and timing of repetitive upper limb 
movements have also been associated with freezing of gait and considered a manifestation of 
akinesia.35  In contrast to healthy elderly, people with PD have difficulty in movement 
anticipation, coordination and timing which are critical for ensuring the correct sequencing of 
postural reactions and for ensuring postural stability.36  These results are in contrast to the 
significance of individual items of speech, gait and postural stability reported previously,1 
which were considered to be related to axial motor features. 
 
The majority of the functional tests in this study, which are commonly used to determine 
postural stability and falls risk in older people, showed differences between fallers and non-
fallers.  The exceptions were the functional reach test and the PPA test.  The magnitudes of 
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these differences were small, however, and they achieved only moderate sensitivity and 
specificity.  This probably renders them unviable as individual screening tools for detecting 
PD individuals at risk of falls, particularly when they are in the early stage of the disease and 
are active and independently living in the community. 
 
The lack of difference for the overall falls risk score derived from the PPA was surprising 
given that it is designed to provide a disease independent assessment of falls risk.26  This is 
probably because the tests and falls risk equations have been derived for older people at risk 
of multiple falls.  However, several of its component tests revealed significant differences 
between fallers and non-fallers and highlight the importance of assessing potential 
contributing physiological falls risk factors.17  The difference in touch thresholds between 
fallers and non-fallers indicates that a reduction in peripheral sensation could be associated 
with the increased postural instability that was observed in fallers.  Increased touch 
thresholds37 and cutaneous denervation38 have been reported for people with PD.  This 
indicates that there is a deficit in peripheral and central mechanisms involved in sensation and 
perception.  Decreased leg strength is also a potential risk factor for falls in PD,17 as has been 
reported for community dwelling older people39, and may be an important modifiable factor 
for falls prevention programs.  An important finding was the difference in postural sway 
when standing on a firm surface with eyes open.  In this situation participants have full 
availability of sensory cues yet, despite this, fallers still swayed more than non-fallers.  
Increased postural sway has been reported for retrospective40 and prospective17 PD falls 
studies.  Community dwelling older people at risk of falls perform worse when standing on a 
foam surface.  It appears that a combination of decreased peripheral somatosensory 
information and decreased leg strength may have contributed to the increased postural 
instability particularly as this occurred in the absence of any differences in visual function. 
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Practically, the test battery is easy to implement and takes only a short time to administer.  
The UPDRS is a routine clinical assessment and the UPDRS II or III score can be substituted 
for the UPDRS total score.  The FOG questionnaire takes only 5 minutes and could be 
completed by the patient prior to their appointment.  The Tinetti takes approximately 5 
minutes to complete and the measure of postural sway on a firm surface less than two 
minutes.  These latter tests could be completed by an allied health professional.  
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FIGURE CAPTIONS 
Figure 1 short title: UPDRS odds ratios. 
Figure 1: Odds ratios and 95% confidence intervals for the individual components of the 
UPDRS for individual items (top) and all items combined (bottom). 
 
Figure 2 short title: Multivariate model ROC. 
Figure 2: Receiver operating curves for multivariate model using (A) the whole sample; (B) 
sub-sample who had not previously fallen; (C) whole sample leave-one-out validation; (D) 
sub-sample leave-one-out validation. 
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Table 1. Demographic and disease statistics 
Data are mean (SD) and ranges or absolute numbers and percentages. ** p<0.01 * p<0.05. Test 1 = independent samples t-test; Test 2 = χ2 test 
 
   Prospective Falls    
 All Patients   (n = 101)  Non-Fallers (n = 53) Fallers (n = 48)  Test p-value 
Age (yrs)  66.4 (8.2); 43 - 84   66.9 (8.4); 49 - 82  65.8 (8.0); 43 - 84  1 0.480 
Gender (male)  67.3%   37.6%  29.7%  2 0.325 
MMSE  28.0 (1.9); 21 - 30   28.2 (1.7); 24 - 30  27.7 (2.1); 21 - 30  1 0.265 
Previous Falls    1.9 (10.3); 0 - 100     0.3 (0.9); 0 - 6   3.8 (15.5); 0 - 100  1 0.157 
Height (cm) 168.3 (8.2); 149.8 - 188.3  168.2 (7.7); 149.8 - 181.0 168.4 (8.8); 151.6 - 188.3  1 0.873 
Weight (kg)  72.5 (13.5); 43.4 - 112.9   71.3 (13.2); 43.4 - 104.7  73.8 (13.9); 43.8 - 112.9  1 0.363 
BMI (kg/m2)  25.6 (4.6);  17.8 - 42.5   25.2 (4.2); 17.8 - 38.5  26.1 (5.0); 18.1 - 42.5  1 0.320 
        
Disease Duration (yrs)   6.1 (4.4); 0.5 - 21.3    4.9 (3.3); 0.5 - 14.0   7.3 (5.2); 0.7 - 21.3  1 0.007** 
Activities of Daily Living  82.1 (9.4); 50 - 100   84.5 (7.8); 70 - 100  79.6 (10.4); 50 - 98  1 0.014* 
Freezing of Gait   4.8 (4.9); 0 - 21    3.1 (3.4); 0 - 12   6.8 (5.6); 0 - 21  1 <0.001** 
Levodopa dose (mg/day) 661.3 (485.2); 0 - 3328  607.9 (301.1); 0 - 1530 723.0 (632.9); 0 - 3328  1 0.264 
Dopamine agonist use  43.6%   15.6%  22.7%  2 0.100 
        
Hoehn & Yahr   2.1 (0.8); 1.0 - 4.0    2.0 (0.8); 1.0 - 3.5   2.3 (0.7); 1.0 - 4.0  1 0.053 
UPDRS I   2.4 (2.1); 0 - 10    2.1 (1.8); 0 - 6   2.7 (2.3); 0 - 10  1 0.169 
UPDRS II  10.2 (5.2); 1 - 26    8.5 (4.1); 1 - 18  12.0 (5.8); 1 - 26  1 0.002** 
UPDRS III  18.7 (9.2); 3.5 - 43.0   16.4 (8.8); 3.5 - 41.5  21.3 (9.1); 4.0 - 43.0  1 0.012* 
UPDRS Total  32.8 (13.4); 11.0 - 66.5   28.5 (12.6); 12.0 - 65.5  37.5 (12.7); 11.0 - 66.5  1 0.001** 
UPDRS IV        
Dyskinesia present  32.1%  11.9% 20.2%  2 0.037* 
Off state occurrence  43.4%  20.5% 22.9%  2 0.263 
Symptomatic orthostasis  18.1%  2.4% 15.7%  2 <0.001** 
Sleep disturbance  38.1%  14.3% 23.8%  2 0.021* 
PIGD   4.0 (2.8); 0 - 11    3.1 (2.2); 0 - 9   4.9 (3.1); 0 - 11  1 0.002** 
PD Sub-type        
TDT  19.5%  14.9%   4.6%  
2 0.084 ART  77.1%  36.8%  40.3%  
MT    3.4%    1.1%    2.3%  
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Table 2. Functional balance, mobility and falls risk tests 
    Prospective Falls   
  All Patient (n = 101) Non-Fallers (n = 53) Fallers (n = 48) p-value 
Tinetti     
Balance 15.0 (1.2); 11 – 16 15.5 (0.7); 13 - 16) 14.5 (1.4); 11 - 16 <0.001** 
Gait 10.9 (1.4); 5 – 12 11.3 (0.8); 10 - 12) 10.4 (1.7); 5 - 12 0.002** 
Total 25.9 (2.2); 18 – 28 26.8 (1.1); 24 – 28 24.9 (2.7); 18 - 28 <0.001** 
Berg Balance Scale 53.6 (2.8); 42 – 56 54.2 (1.9); 46 – 56 52.8 (3.4); 42 - 56 0.013* 
Functional Reach (cm) 27.6 (6.2); 12.7 - 44.5 27.7 (5.1; 12.7 - 41.9 27.6 (7.2); 14.0 - 44.5 0.964 
Timed Up & Go (s) 10.1 (2.7); 5.0 - 19.0 9.4 (2.2); .0 - 19.0 10.8 (3.0); 5.0 - 18.0 0.010* 
Physiological Profile Assessment Falls Risk 1.4 (1.0); -1.0 - 4.9 1.2 (1.0); -0.4 - 4.9 1.5 (0.9); -1.0 - 3.5 0.164 
     
Component Tests of Physiological Profile 
Assessment 
    
Vision     
Visual Acuity: High Contrast 0.0 (0.1); -0.2 - 0.5 0.0 (0.1); -0.2 - 0.3 0.0 (0.1); -0.2 - 0.5 0.461 
Visual Acuity: Low Contrast 0.3 (0.2); -0.1 - 0.8 0.3 (0.2); 0.0 - 0.8 0.3 (0.2); -0.1 - 0.8 0.250 
Contrast Sensitivity: Melbourne Edge Test 20.1 (1.9); 16 – 24 20.3 (2.0); 17 – 24 20.0 (1.8); 16 - 23 0.427 
Peripheral Sensation     
Touch 5.1 (1.6); 2 – 8 4.8 (1.5); 2 – 8 5.4 (1.6); 2 - 8 0.045* 
Vibration 39.8 (20.2); 3.6 - 86.1 39.1 (17.3); 5.9 - 76.0 40.6 (23.2); 3.6 - 86.1 0.742 
Proprioception 2.4 (1.4); 0.3 - 8.2 2.3 (1.2); 0.3 - 5.5 2.4 (1.6); 0.3 - 8.2 0.631 
Strength (kg)     
Knee flexion 13.2 (5.3); 2.5 - 26.0 13.6 (5.8); 2.5 - 25.4 12.8 (4.7); 3.8 - 26.0 0.452 
Knee extension 30.3 (13.9; 9.0 - 83.3 33.0 (16.1); 9.0 - 83.3 27.4 (10.3); 10.4 - 53.1 0.045* 
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Ankle dorsiflexion 14.3 (5.6); 1.7 – 27 14.8 (6.1); 1.7 - 27.0 13.7 (5.2); 4.0 - 25.0 0.355 
Reaction Time (ms)     
Hand 301.0 (75.0); 189.0 - 578.3 306.6 (77.2); 208.6 - 578.3 294.9 (72.9); 189.0 - 572.0 0.439 
Foot 378.5 (90.2); 225.0 - 651.8 384.5 (100.1); 247.5 - 629.6 372.0 (78.7); 225.0 - 651.8 0.487 
Balance (mm)     
Firm Surface:        Eyes Open – AP 17.5 (8.4); 6 – 46 14.8 (7.1); 6 – 41 20.4 (8.8); 8 - 46 0.001** 
– ML 15.5 (13.1); 1 – 80 13.1 (9.2); 1 – 42 18.2 (16.2); 1 - 80 0.057 
Eyes Closed – AP 23.1 (14.0); 6.5 - 99.0 20.1 (12.0); 6.5 - 63.0 26.5 (15.3); 10 - 99 0.022* 
 – ML 17.7 (16.0); 1 – 97 15.5 (9.8); 2 – 38 20.1 (20.7); 1 - 97 0.170 
Foam Surface:      Eyes Open – AP 30.5 (13.0); 12.5 - 78.0 28.3 (12.5); 12.5 – 69.0 33.0 (13.3); 16 - 78 0.079 
 – ML 32.6 (20.6); 4 – 142 29.9 (22.4); 4 – 142 35.7 (18.1); 6.5 - 85.0 0.170 
Eyes Closed – AP 54.2 (25.1); 13 – 145 51.9 (23.5); 13 – 145 56.7 (26.7); 22 - 125 0.371 
– ML 46.6 (25.7); 5 – 143 43.4 (20.5); 5 – 92 50.0 (30.2); 5.5 - 143.0 0.227 
Data are mean (SD) and ranges or absolute numbers and percentages. ** p<0.01 * p<0.05.  
 
Kerr  25 
Table 3. ROC analyses 
 Accuracy (% ) Area Under 
Curve 
Sensitivity Specificity 
Demographics     
Age 0.46 0.45 0.50 0.43 
Previous falls 0.71 0.72 0.59 0.79 
     
Disease Specific Measures     
Disease Duration 0.61 0.63 0.63 0.62 
Activities of Daily Living 0.56 0.63 0.62 0.50 
Freezing of Gait 0.67 0.73 0.75 0.59 
Levodopa dose 0.61 0.52 0.54 0.51 
     
Hoehn &Yahr 0.55 0.61 0.88 0.35 
UPDRS I 0.53 0.57 0.48 0.61 
UPDRS II 0.63 0.68 0.64 0.67 
UPDRS III 0.63 0.67 0.64 0.60 
UPDRS Total 0.66 0.70 0.74 0.63 
PIGD 0.60 0.67 0.66 0.62 
     
Functional Tests     
Tinetti     
Balance 0.68 0.71 0.65 0.66 
Gait 0.64 0.64 0.65 0.45 
Total 0.71 0.72 0.67 0.59 
Berg Balance Scale 0.60 0.61 0.65 0.51 
Functional Reach 0.52 0.52 0.52 0.53 
Timed Up & Go 0.63 0.65 0.69 0.62 
Physiological Profile 
Assessment Falls Risk 
0.64 0.64 0.68 0.69 
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